➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
Dow
Moodys
Johnson and Johnson

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Litigation Details for Allergan, Inc. v. Ferrum Ferro Capital, LLC (C.D. Cal. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Allergan, Inc. v. Ferrum Ferro Capital, LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Allergan, Inc. v. Ferrum Ferro Capital, LLC
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Allergan, Inc. v. Ferrum Ferro Capital, LLC (C.D. Cal. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-06-19 1 Complaint (Attorney Civil Case Opening) Batoosingh , including U.S. Patent Nos. 7,030,149 (“the ’149 patent”), 7,320,976, 22 7,642,258, 8,133,890…interest in each of 24 these six patents, including the ’149 patent. 25 22. COMBIGAN® or…claim of each of the six patents listed above, including the 27 ’149 patent. 28 23. Because…expiration of 7 Allergan’s patents covering COMBIGAN®, including the ’149 patent. These 8 ANDAs were filed…infringed Allergan’s duly issued patents, including 13 the ’149 patent. 14 25. In response, External link to document
0000-00-00 26 Motion to Strike Partes Review of U.S. Patent 9 No. 7,030,149 (hereinafter the “‘149 patent”) as the America Invents…four patents, finding them obvious and therefore not patentable. 9 As to the fourth patent, the …petitioning the United States Patent and Trademark Office’s 9 (“USPTO’s”) Patent Trial & Appeal Board…FFC’s position that Claim 4 of the ‘149 Patent is non-patentable as 24 obvious, Allergan cannot demonstrate… claims of the '463 patent 16 and claim 4 of the '149 patent cannot be reconciled. 17 External link to document
0000-00-00 27 Exhibit A - Allergan v Sandoz ED TX drugs. (D.I. 239, Trial Tr. Day 1 (PM) at 64:10-66:3 (Batoosingh).) By contrast, a ―fixed combination… United States Patent Nos. 7,030,149 (―the ‗149 patent‖); 7,320,976 (―the ‗976 patent‖); 7,323,463 (… (―the ‗463 patent‖); and 7,642,258 (―the ‗258 patent‖) (collectively, the ―patents-in-suit‖). The Court…claim 4 of the ‗149 Patent, claim 1 of the ‗976 patent, claims 1-6 of the ‗463 Patent, and claims 1-9 of… E. The Patents-in-Suit 31. The patents-in-suit are U.S. Patent Nos. 7,030,149 ( External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Dow
McKinsey
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.